Results 41 to 50 of about 631 (89)

Machine Learning–Augmented Precision Dosing: Integrating Pharmacokinetic Modeling With Clinical Decision Support

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 11, November 2026.
ABSTRACT Inter‐individual variability in drug exposure can lead to ineffective therapy or toxicity, particularly in vulnerable patients. Routine model‐informed precision dosing (MIPD) relies mainly on population pharmacokinetic (PopPK) models, Bayesian forecasting, and therapeutic drug monitoring (TDM).
Yunmeng Pang, Bingqi Zhang, Zhiqiu He, Yuliu Li, Jiaxin Yu, Wei Zuo   +5 more
wiley   +1 more source

A Minimal Physiologically‐Based Pharmacokinetic Model for Tacrolimus in Living‐Donor Liver Transplantation: Perspectives Related to Liver Regeneration and the cytochrome P450 3A5 (CYP3A5) Genotype

CPT: Pharmacometrics & Systems Pharmacology, 2019
In adult patients after living‐donor liver transplantation, postoperative days and the cytochrome P450 3A5 (CYP3A5) genotype are known to affect tacrolimus pharmacokinetics.
Kotaro Itohara, Ikuko Yano, Tetsunori Tsuzuki, Miwa Uesugi, Shunsaku Nakagawa, Atsushi Yonezawa, Hideaki Okajima, Toshimi Kaido, Shinji Uemoto, Kazuo Matsubara   +9 more
doaj   +1 more source

Identifying Dose‐Relevant Covariates With SCOUT: A Case Study of Lorlatinib

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 11, November 2026.
ABSTRACT Molecularly targeted therapeutics, such as lorlatinib, are typically initiated at fixed starting doses with subsequent tolerability‐guided modifications, although substantial interindividual variability in pharmacokinetics and drug exposure may influence both efficacy and safety outcomes.
Yasuhisa Ideno
wiley   +1 more source

Effect of CYP3A5*3 polymorphism on anti-inflamatory therapy in children with bronchial asthma

Медицинский совет, 2019
Previous pharmacogenetic studies demonstrate significant genes’ polymorphisms effect on the efficacy and safety of pharmacotherapy, including in bronchial asthma (BA).
A. K. Zastrozhina, S. V. Zaitseva, E. A. Grishina, K. A. Ryzhykova, O. O. Panfeorova, S. Y. Kalenov, O. I. Soboleva, D. A. Sychyov, I. N. Zakharova   +8 more
doaj   +1 more source

Histone deacetylase inhibitors as venetoclax‐sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives

British Journal of Pharmacology, Volume 183, Issue 21, Page 6261-6290, November 2026.
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley   +1 more source

Pharmacokinetic profiling of imatinib in relation to CYP3A4 activity in leukaemia patients

British Journal of Clinical Pharmacology, Volume 92, Issue 10, Page 3375-3386, October 2026.
Aim Imatinib pharmacokinetics exhibit large interindividual variability because of differences in CYP3A4 activity—the main imatinib‐metabolizing enzyme. While therapeutic drug monitoring is effective, it requires steady‐state conditions and frequent sampling.
Anna Sofie Buhl Rasmussen, Mathilde Rønne Koch, Cecilie Utke Rank, Christen Lykkegaard Andersen, Allan Weimann, Maria Thastrup, Tianwu Yang, Trine Meldgaard Lund, Ib Jarle Christensen, Flemming Nielsen, Tore Bjerregaard Stage, Sara Bisgaard Jensen, Mette Klarskov Andersen, Kjeld Schmiegelow, Kim Dalhoff   +14 more
wiley   +1 more source

Development, Early Verification and Application of a North American Pediatric PBPK Model, Comparison With the North European Pediatric Population

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 10, October 2026.
ABSTRACT Physiologically based pharmacokinetic (PBPK) models are increasingly used in pediatric drug development and matching such models to the target population is an important consideration. A US pediatric PBPK model was developed incorporating four sub‐groups describing physiology and enzymatic/transporter levels for White, African American ...
Trevor N. Johnson, Fiskani Kondowe, Joyce van der Heijden, Saskia N. de Wildt, Iain Gardner, Karen Rowland Yeo   +5 more
wiley   +1 more source

Factors affecting the long-term response to tacrolimus in renal transplant patients: Pharmacokinetic and pharmacogenetic approach

International Journal of Medical Sciences, 2010
Background: The aim of our study was to determine the impact of CYP3A5*1 and CYP3A5*3 on the kinetics of tacrolimus in renal transplant recipients. Material and methods: Forty kidney recipients were selected to participate.
Paraskevi F. Katsakiori, Eirini P. Papapetrou, George C. Sakellaropoulos, Dimitrios S. Goumenos, George C. Nikiforidis, Christodoulos S. Flordellis
doaj  

Differences in Early Tacrolimus Exposure in Kidney Transplant Recipients With and Without CYP3A5 Genotype‐Guided Tacrolimus Dosing

Clinical and Translational Science
CYP3A5 genotype is a known predictor of tacrolimus dose requirements. This single‐center retrospective study evaluated the impact of CYP3A5 genotype‐guided dosing, implemented at our institution in 10/2023, on early tacrolimus exposure.
Amy L. Pasternak, Jenna Schwartz, Brett Vanderwerff, Sebastian Zöllner, Danielle J. Haakinson, Mona Doshi, Jeong M. Park   +6 more
doaj   +1 more source

Comparison of pharmacogenomic guidance in Australian prescribing resources and international pharmacogenomic guidelines

Internal Medicine Journal, Volume 56, Issue 10, Page 1765-1774, October 2026.
Abstract Background Pharmacogenomic‐guided medication management optimises drug therapy to enhance patient outcomes. Despite clinical utility, implementation in Australia remains limited, partly due to the lack of clear and consistent guidance. Aim This study evaluated the presence and consistency of pharmacogenomic testing indication categories and ...
Ruby Soueid, Jackson L. A. Thomas, Luke B. Hesson, Stephen Hughes, Sophie L. Stocker   +4 more
wiley   +1 more source